Jump to content

Coupland, 2011 Antidepressant use and risk of adverse outcomes in older people


Gem
 Share

Recommended Posts

BMJ 2011; 343:d4551 doi: 10.1136/bmj.d4551 (Published 2 August 2011)

Cite this as: BMJ 2011; 343:d4551

Research

Antidepressant use and risk of adverse outcomes in older people: population based cohort study

OPEN ACCESS

 

Carol Coupland, associate professor in medical statistics1, Paula Dhiman, research statistician1, Richard Morriss, professor of psychiatry and community mental health2, Antony Arthur, associate professor in elder care3, Garry Barton, senior lecturer in health economics4, Julia Hippisley-Cox, professor of clinical epidemiology and general practice1

+ Author Affiliations

 

1Division of Primary Care, University of Nottingham, Nottingham NG7 2RD, UK

2Division of Psychiatry, University of Nottingham

3Division of Nursing, University of Nottingham

4Health Economics Group (HEG), School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK

Correspondence to: C Coupland carol.coupland@nottingham.ac.uk

Accepted 13 June 2011

Abstract

 

Objectives To investigate the association between antidepressant treatment and risk of several potential adverse outcomes in older people with depression and to examine risks by class of antidepressant, duration of use, and dose.

 

Design Cohort study of people aged 65 and over diagnosed as having depression.

 

Setting 570 general practices in the United Kingdom supplying data to the QResearch primary care database.

 

Participants 60 746 patients diagnosed as having a new episode of depression between the ages of 65 and 100 years from 1 January 1996 to 31 December 2007 and followed up until 31 December 2008.

 

Main outcome measures Hazard ratios associated with antidepressant use for all cause mortality, attempted suicide/self harm, myocardial infarction, stroke/transient ischaemic attack, falls, fractures, upper gastrointestinal bleeding, epilepsy/seizures, road traffic accidents, adverse drug reactions, and hyponatraemia, adjusted for a range of potential confounding variables. Hazard ratios were calculated for antidepressant class (tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants), dose, and duration of use and for commonly prescribed individual drugs.

 

Results 54 038 (89.0%) patients received at least one prescription for an antidepressant during follow-up. A total of 1 398 359 antidepressant prescriptions were issued: 764 659 (54.7%) for selective serotonin reuptake inhibitors, 442 192 (31.6%) for tricyclic antidepressants, 2203 (0.2%) for monoamine oxidase inhibitors, and 189 305 (13.5%) for the group of other antidepressants. The associations with the adverse outcomes differed significantly between the antidepressant classes for seven outcomes. Selective serotonin reuptake inhibitors were associated with the highest adjusted hazard ratios for falls (1.66, 95% confidence interval 1.58 to 1.73) and hyponatraemia (1.52, 1.33 to 1.75) compared with when antidepressants were not being used. The group of other antidepressants was associated with the highest adjusted hazard ratios for all cause mortality (1.66, 1.56 to 1.77), attempted suicide/self harm (5.16, 3.90 to 6.83), stroke/transient ischaemic attack (1.37, 1.22 to 1.55), fracture (1.64, 1.46 to 1.84), and epilepsy/seizures (2.24, 1.60 to 3.15), compared with when antidepressants were not being used. Tricyclic antidepressants did not have the highest hazard ratio for any of the outcomes. Significantly different associations also existed between the individual drugs for the same seven outcomes; trazodone (tricyclic antidepressant), mirtazapine, and venlafaxine (both in the group of other antidepressants) were associated with the highest rates for some of these outcomes. Absolute risks over 1 year for all cause mortality were 7.04% for patients while not taking antidepressants, 8.12% for those taking tricyclic antidepressants, 10.61% for selective serotonin reuptake inhibitors, and 11.43% for other antidepressants.

 

Conclusions Selective serotonin reuptake inhibitors and drugs in the group of other antidepressants were associated with an increased risk of several adverse outcomes compared with tricyclic antidepressants. Among individual drugs, trazodone, mirtazapine, and venlafaxine were associated with the highest risks for some outcomes. As this is an observational study, it is susceptible to confounding by indication, channelling bias, and residual confounding, so differences in characteristics between patients prescribed different antidepressant drugs that could account for some of the associations between the drugs and the adverse outcomes may remain. Further research is needed to confirm these findings, but the risks and benefits of different antidepressants should be carefully evaluated when these drugs are prescribed to older people.

 

FootnotesWe thank the practices and patients who provide data to QResearch. This project was funded by the NIHR Health Technology Assessment Programme (project number 06/42/01) and will be published in full in Health Technology Assessment. Further information about the project is available on the HTA programme website (www.hta.ac.uk/).

Contributors: CC was involved in the conception and design of the study, analysing and interpreting data, and reviewing the literature; she wrote the draft manuscript. PD was involved in the design of the study, statistical analysis, interpreting data, and reviewing the literature. RM and AA were involved in the conception and design of the study, interpretation of data, and reviewing the literature. GB was involved in interpretation of data and reviewing the literature. JH-C was involved in the conception and design of the study, extracted the data, and was involved in interpretation of data and reviewing the literature. All authors critically reviewed the paper. CC is the guarantor.

Funding: This project was funded by the NIHR Health Technology Assessment Programme (project number 06/42/01). The views and opinions expressed are those of the authors and do not necessarily reflect those of the Department of Health.

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: all authors had financial support from the NIHR Health Technology Assessment Programme (project number 06/42/01) for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; JH-C is director of QResearch, which is a not for profit venture between the University of Nottingham and EMIS (commercial supplier of general practice clinical computer systems), and director of ClinRisk Ltd (medical software company); RM has received financial support for speaking at meetings sponsored by several pharmaceutical companies about the non-drug treatment of depression and bipolar disorder; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The project was independently peer reviewed by the QResearch Scientific Board and has been reported to Trent Research Ethics Committee in accordance with the agreed procedure.

Data sharing: The patient level data from the QResearch databases are specifically licensed according to the governance framework. See www.qresearch.org for further details.

 

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

 

http://www.bmj.com/content/343/bmj.d4551

 

 

I came off Seroxat in August 2005 after a 4 month taper. I was initially prescibed a benzo for several months and then Prozac for 5 years and after that, Seroxat for 3 years and 9 months.

 

"It's like in the great stories Mr.Frodo, the ones that really mattered. Full of darkness and danger they were, and sometimes you didn't want to know the end because how could the end be happy? How could the world go back to the way it was when so much bad had happened? But in the end it's only a passing thing this shadow, even darkness must pass. A new day will come, and when the sun shines it'll shine out the clearer."  Samwise Gamgee, Lord of the Rings, The Two Towers

Link to comment
Share on other sites

  • Administrator

Good job, Gem.

 

The article is accompanied by an editorisl in the BMJ, abstract at http://www.bmj.com/content/343/bmj.d4660

 

BMJ 2011; 343:d4660 doi: 10.1136/bmj.d4660 (Published 2 August 2011)

Cite this as: BMJ 2011; 343:d4660

 

Editorial

 

Antidepressants in elderly people

 

Ian B Hickie, professor

 

+ Author Affiliations

 

1Brain and Mind Research Institute, University of Sydney, Camperdown 2050, NSW, Sydney, Australia

 

ian.hickie@sydney.edu.au

 

Careful monitoring is needed for adverse effects, particularly in the first month of treatment

 

Because older people with clinical depression have high rates of concurrent medical illness, particularly cerebrovascular disease, they are at high risk of adverse events from most antidepressants. 1 However, given the likelihood of poor functional outcomes and the increased risk of premature death by suicide, vascular disease, accident, or injury, safe and effective interventions are needed. 1 2 3 In the linked cohort study (doi: 10.1136/bmj.d4551 ), Coupland and colleagues assess the association between antidepressant treatment and risk of adverse outcomes in older people with depression in primary care. 4

 

Before the 1990s, enthusiasm for drug treatment of depression was tempered by the risks associated with tricyclic antidepressants or monoamine oxidase inhibitors. With the arrival of selective serotonin reuptake inhibitors (SSRIs), which were reported to have far fewer major side effects treatment increased greatly, particularly in primary care settings. 5 However, clinical trials had rarely focused on direct comparisons of benefits versus harms in older patients.

 

Although the relative benefits of new antidepressants are now clearer, 6 there are still valid concerns about prescribing to younger 7 and older patients. Although the reduction in suicide with the use of antidepressants is evident in older people, 8 it has been harder to determine whether increased prescribing may also cause harm.

 

Coupland and colleagues assessed the effects of antidepressants in 60 706 patients aged 65 and over with a newly diagnosed episode of …

 

[end of abstract]

 

Full text of this article would be appreciated, if anyone can donate it.

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

  • 2 years later...
  • Administrator

This is not medical advice. Discuss any decisions about your medical care with a knowledgeable medical practitioner.

"It has become appallingly obvious that our technology has surpassed our humanity." -- Albert Einstein

All postings © copyrighted.

Link to comment
Share on other sites

 Share

×
×
  • Create New...

Important Information

Terms of Use Privacy Policy